Top Markets
Coin of the day
RegeneRx Biopharmaceuticals, Inc. RegeneRx Biopharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc.

RGRX
Rank in Stocks #42502
RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the... RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.
Share Price
$0.0007
Last synced: 2026-08-11
Market Cap
$1.05K
Change (1 day)
0.00%
Change (1 year)
250.00%
Country
US
Trade RegeneRx Biopharmaceuticals, Inc. (RGRX)

Category

Revenue for RegeneRx Biopharmaceuticals, Inc. (RGRX)
Revenue in Aug 2026 TTM: 0
According to RegeneRx Biopharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for RegeneRx Biopharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$6.02B -
NL
- -
CH
$10.11B -
BE
- -
KR